We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Collagen Solutions Plc | COS | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 6.625 | 00:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 6.625 | 6.625 |
| Top Posts |
|---|
Posted at 12/11/2020 14:05 by moontheloon Still positive about Polx tutte? I find it hard to get positive at mo.. When been immersed in cos for years.. But seems like a good product... |
Posted at 09/10/2020 07:45 by 40 fathoms NXC I have to say I agree with both Moon and WTT with respect to the COS board. I think their performance has been woeful, almost to the point of incompetence in their handling of matters this year. Clearly they are people you know well and as a man of good standing I would not expect you to do anything other than disagree with that assessment. However, I am absolutely certain if your health had allowed you to remain as chairman we would today have a clear understanding (for better or worse) where things stood with Chondro, and if indeed 6.5p is the right price for the business why 6.5p is the right price and an understanding of how the board came to that decision. As of today we have none of these understandings. When you stepped down, the board lost all of its entrepreneurial spirit and the understanding of how to protect and treat the small investor. To my mind only Mr. Gillies comes across as being suitable for the board of a listed company. I hope your health situation is stable and I wish you well. |
Posted at 03/9/2020 15:53 by nxc WTT/Moon - I do understand where you are coming from and value is in the eye of the beholder so I respect your desired outcome.My reasoning behind the downside risk is that if the offeror walks away then the Company will almost certainly require to raise money if only to satisfy the Auditor's on Going Concern where the bar for a clean audit opinion has been raised significantly. My instinct is that a minimum of £4m would be needed and I think in that sense Rosen would have the whip hand in setting the price which would be nearer 1p than 2p. None of the EIS/VCT funds can participate - that leaves myself/Helium and Brett Gordon out of the substantial Shareholders ( apologies to substantial <3% holders but I do not have access to an upto date register)to fund the gap that Rosen cannot fill as they will be limited to an overall shareholding of 29.9%. The dilutory impact is significant and my biggest concern above all others is the impact on Management - they have been through the wringer and contrary to the view that they are self-serving with snouts in a trough they are an incredibly hard working group who I fear are fatigued. Life is not a straight line and the assumptions being made about future value assume most of the dominoes will fall COS's way - experience tells you that is unlikely. COS is vulnerable to the loss of key personnel and we should bear that in mind. |
Posted at 03/9/2020 12:40 by nxc Moon - I have not posted historically (pot/kettle) as up until July 19 it was not possible as I am the former Chairman of COS - I think you fundamentally mis-understand the situation but I respect that as a Shareholder you have the right to air your views and vote in accordance with what you consider to be your best interests. |
Posted at 03/9/2020 10:08 by nxc Interesting observations WTT - it will require deep pockets to fund COS given its Shareholder base. You are also discounting the downside risks to the business. |
Posted at 01/9/2020 09:12 by interstellar Cos crock of sh%%. Been in since the heady heights of 13p and its just been one missed target after another yet still taken their bonuses and options. Woeful! |
Posted at 21/7/2020 06:06 by moontheloon 21 July 2020Collagen Solutions Plc(the "Company") Trading UpdateNew contract win enhances revenues Collagen Solutions Plc (AIM: COS), the developer and manufacturer of biomaterials and regenerative medicines for the enhancement and extension of human life, announces an update to its order book/contracted development revenues following the signing of a significant new contract.The Company has performed well, and has recently finalised a number of contracts, including the Novabone supply agreement announced on 7 July and a new supply agreement with an existing client for a long-term supply with larger contracted volumes as at 15 July 2020. With the new contract in place, the Company now has orders or contracted development milestones for FY 2021, together with revenue already recognised through the first three months of the financial year, worth approximately £4.3m (representing 108% of the sales in the last financial year). Jamal Rushdy, CEO of Collagen Solutions said: "We are delighted to have secured this new contract. In our trading update announced in June, we said our order book was at approximately £3.3m, which was 82% of FY 2020 revenue. This further strengthening of the order book now puts us in a strong position to deliver a successful financial year. We remain confident that we can generate value to shareholders over the medium term."Collagen Solutions PlcD: +44 (0)20 7933 8786M: +44 (0)7876 741 001anna.dunphy@walbr |
Posted at 18/5/2020 06:27 by moontheloon Collagen Solutions plc(the "Company") Strategic Review and Formal Sale Process Update Collagen Solutions Plc (AIM: COS), the developer and manufacturer of biomaterials and regenerative medicines for the enhancement and extension of human life, is providing an update on the Company's strategic review and formal sale process and receipt of multiple indications of interest. On 16 April 2020, the Company announced that following receipts of interest it decided to conduct a formal review of various strategic options available to the Company to maximise value for shareholders. These options included, but were not limited to, the potential sale of the Company or the sale of one or more of the Company's assets. To facilitate discussions with interested parties the Company announced the commencement of a "formal sale process" as set out by the Takeover Code. As part of the formal sale process or the sale of one of more of the Company's assets, parties were requested to submit an indication of interest to the Company's financial advisers by no later than 5.00 p.m. (London time) on 15 May 2020. The Company has received indications of interest in respect of (i) a purchase of the Company as a whole (ii) a purchase or investment in a part of the business of the Company and (iii) a refinancing of the Company. The Company looks forward to engaging with relevant parties in a constructive and positive manner with a view to optimising value for shareholders.There can be no certainty that an offer will be made, nor as to the terms on which any offer will be made, or that any transaction will ensue. |
Posted at 10/4/2019 07:33 by newtothisgame3 More than Money: Collagen Solutions09/04/2019 · #Collagen #Solutions (#COS) |
Posted at 01/2/2019 07:40 by moontheloon Collagen Solutions PLC ChondroMimetic® UpdateSource: UK Regulatory (RNS & others)TIDMCOSRNS Number : 5866OCollagen Solutions PLC31 January 201931 January 2019Collagen Solutions plc("Collagen Solutions", the "Company" or the "Group")ChondroMimet |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
